Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 191

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 191
---
$1,775 $(1,244)$— $531 

See accompanying notes.

4

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(unaudited)

Three Months EndedMarch 31,20252024Cash flow from operating activitiesNet loss$(112)$(4)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense16 20 Depreciation and amortization3 3 Noncash lease expense2 2 Impairment of long-lived assets— 20 Amortization of discounts on marketable securities(4)(6)Changes in operating assets and liabilities:Receivable from collaboration partners ($2 and ($1) from a related party)5 13 Other assets ($— and $6 from a related party)— 5 Accounts payable3 (1)Deferred revenue (($28) and ($54) to a related party)(28)(42)Other liabilities(17)(12)Net cash used in operating activities(132)(2) Cash flow from investing activitiesPurchases of marketable securities(353)(387)Proceeds from maturities of marketable securities360 222 Proceeds from sales of marketable securities26 — Purchases of property and equipment(1)(4)Net cash provided by (used in) investing activities32 (169) Cash flow from financing activitiesProceeds from issuance of common stock ($14 and $228 from a related party)142 228 Proceeds from issuance of common stock pursuant to equity award plans— 1 Net cash provided by financing activities142 229 Net increase in cash, cash equivalents and restricted cash42 58 Cash, cash equivalents and restricted cash at beginning of period153 130 Cash, cash equivalents and restricted cash at end of period$195 $188  Non-cash investing and financing activities:Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities$— $1 

See accompanying notes.

5

ARCUS BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1. Organization, liquidity and capital resources

Organization Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage biopharmaceutical company